Table 2. Patient characteristics.

Data represented as n (%); *Combination of any two or more CTLA-4, PD-1, and PD-L1 inhibitors; †Any other antineoplastic treatment not belonging to the class of ICIs specifically listed.

CTLA-4, cytotoxic T-lymphocyte–associated protein 4; ECOG PS, Eastern Cooperative Oncology Group performance status; ICI, immune checkpoint inhibitor; ICI Comb, combinations of ICIs; PD-1, programmed cell death 1; PD-L1, programmed cell death ligand 1.

	Patients (N = 69,140)	Treatment courses (N = 85,433)
Age at baseline
18–29	275 (0.40)	382 (0.45)
30–39	937 (1.36)	1,210 (1.42)
40–49	2,810 (4.06)	3,502 (4.10)
50–59	10,556 (15.27)	12,897 (15.10)
60–64	9,700 (14.03)	11,719 (13.72)
65–69	11,662 (16.87)	13,902 (16.27)
70–79	23,106 (33.42)	28,022 (32.80)
> 80	11,393 (16.48)	13,799 (16.15)
Race
Asian	1,140 (1.64)	1,412 (1.65)
Black	4,373 (6.32)	5,389 (6.31)
Hispanic	91 (0.13)	113 (0.13)
Other	8,468 (12.24)	10,488 (12.27)
White	48,891 (70.71)	60,665 (71.01)
Unknown	6,177 (8.93)	7,376 (8.63)
Type of cancer
Lung	29,217 (42.26)	34,527 (40.41)
Secondary malignancies and metastatic disease	19,967 (28.88)	24,412 (28.57)
Melanoma	5,933 (8.58)	7,962 (9.32)
Kidney	2,738 (3.96)	3,190 (3.73)
Bladder	2,283 (3.30)	2,640 (3.09)
Prostate	357 (0.52)	429 (0.50)
Liver	1,107 (1.60)	1,259 (1.47)
Liver carcinoma	660 (0.95)	739 (0.87)
Other	9,496 (13.73)	11,014 (12.89)
ECOG PS
Missing	18,076 (26.14)	21,102 (24.70)
0	16,302 (23.58)	19,258 (22.54)
1	26,601 (38.47)	30,794 (36.04)
2	10,563 (15.28)	11,618 (13.60)
3	2,342 (3.39)	2,503 (2.93)
4	146 (0.21)	158 (0.18)
Treatment class
CTLA-4 inhibitors	2,007 (2.90)	2,526 (2.96)
PD-1 inhibitors	48,295 (69.85)	57,421 (67.21)
PD-L1 inhibitors	6,712 (9.71)	7,608 (8.91)
ICI Comb*	5,025 (7.27)	5,274 (6.17)
ICI plus antineoplastic†	12,073 (17.46)	12,604 (14.75)